Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer by Al B Benson, Anirban Maitra, Milind Javle, Michael Overman, Richard E Davis, Pankaj Vats, Chandan Kumar-Sinha, Lianchun Xiao, Niharika B Mettu, Edwin R Parra, Charles D Lopez, Veerendra Munugalavadla, Priti Patel, Lin Tao, Sattva Neelapu

Get full text

Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study by Bernard A Fox, Chichung Wang, Kristin Roman, Carla Coltharp, Carmen Ballesteros-Merino, Shawn M Jensen, Janis M Taube, David L Rimm, Cliff Hoyt, Mei Jiang, Edwin R Parra, Ignacio Wistuba, Elizabeth L Engle, John McGuire, Bethany Remeniuk, Darren Locke

Get full text

Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively i... by Jing Wang, Ignacio I Wistuba, Alexandre Reuben, Chantale Bernatchez, Tina Cascone, Jianjun Zhang, Boris Sepesi, Edwin R Parra, Ara A Vaporciyan, Kyle G Mitchell, Lixia Diao, Tatiana Karpinets, Marcelo V Negrao, Hai T Tran, Erin M Corsini, Lorenzo Federico, Hitoshi Dejima, Alejandro Francisco-Cruz, Mara B Antonoff, Stephen G Swisher, John V Heymach, Don L Gibbons, Cara L Haymaker

Get full text

Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a sing... by Shiao-Pei Weathers, Xiqi Li, Haifeng Zhu, Ashish V. Damania, Mark Knafl, Brian McKinley, Heather Lin, Rebecca A. Harrison, Nazanin K. Majd, Barbara J. O’Brien, Marta Penas-Prado, Monica Loghin, Carlos Kamiya-Matsuoka, W. K. Alfred Yung, Luisa M. Solis Soto, Dipen M. Maru, Ignacio Wistuba, Edwin R. Parra Cuentas, Sharia Hernandez, Andrew Futreal, Jennifer A. Wargo, Katja Schulze, Walter C. Darbonne, Nadim J. Ajami, Scott E. Woodman, John F. de Groot

Get full text

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors by Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna

Get full text